Article
Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamide.
Oncotarget - 13 Sept 2016
Hoefer Julia, Akbor Mohammady, Handle Florian, Ofer Philipp, Puhr Martin, Parson Walther, Culig Zoran, Klocker Helmut, Heidegger Isabel
Abstract excerpt
Enzalutamide is an androgen receptor (AR) inhibitor approved for therapy of metastatic castration resistant prostate cancer. However, clinical application revealed that 30 to 40% of patients acquire resistance after a short period of treatment. Currently, the molecular mechanisms underlying such resistances are not completely understood, partly due to a lack of model systems. In the present study we established...
Topics
- Androstenes
- Anilides
- Benzamides
- Cell Line, Tumor
- Cell Proliferation
- Cell Survival
- Drug Resistance, Neoplasm
- Gene Expression Regulation, Neoplastic
- Humans
- Male
- Mutation
- Nitriles
- Phenylthiohydantoin